Prevention of chickenpox in reproductive-age women: Cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles

被引:30
|
作者
Smith, WJ
Jackson, LA
Watts, DH
Koepsell, TD
机构
[1] Univ Washington, Robert Wood Johnson Clin Scholars Program, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA
[3] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA
来源
OBSTETRICS AND GYNECOLOGY | 1998年 / 92卷 / 04期
关键词
D O I
10.1016/S0029-7844(98)00221-X
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate economic and clinical outcomes of a program of routine prenatal serotesting for variceila and postpartum vaccination of seronegative women. Methods: An analytic cost-effectiveness model was constructed to compare the current strategy of no serotesting with 1) selective serotesting of pregnant women without a prior history of chickenpox and 2) serotesting of all pregnant women. In both serotesting strategies, seronegative women were vaccinated postpartum The model followed a hypothetical cohort of 4 million women over 20 years. Costs and chickenpox disease outcomes during and outside of subsequent pregnancies were considered. The incremental cost-effectiveness (cost per adult chickenpox case prevented) of selective serotesting compared with the current strategy was measured. Results: Compared to no testing, selective serotesting would prevent 43% (48,577 of 112,654) of adult chickenpox cases, save $21.8 million in discounted medical and work loss costs from the societal perspective, and cost $1126 per case prevented from the health payer's perspective (medical costs only). The model was sensitive to varicella seroprevalence and incidence of chickenpox among susceptible women but was relatively insensitive to the cost of serologic testing and vaccination. Compared with selective serotesting, the serotest-all strategy would prevent an additional 15,645 cases, at a societal cost of $7653 per additional case prevented. Conclusion: The selective serotesting strategy could prevent nearly half of chickenpox cases among this cohort and is cost-saving from the societal perspective. From the health payer's perspective, it compares favorably with other generally accepted preventive practices. It should be considered for prevention of chickenpox among women of childbearing age. (Obstet Gynecol 1998;92:535-45. (C) 1998 by The American College of Obstetricians and Gynecologists.).
引用
收藏
页码:535 / 545
页数:11
相关论文
共 50 条
  • [41] 47-Fold rise of diabetes in childbearing age Chilean women: Markov model and cost-effectiveness of prevention of birth defects
    Olmos, Pablo
    Borzone, Gisella
    Poblete, Andres
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2018, 44 (09) : 1719 - 1730
  • [42] The cost-effectiveness of a volunteer lifestyle coaching weight reduction programme for women attending routine breast cancer screening - results from the actwell trial
    McNamee, P.
    Treweek, S.
    Anderson, A.
    INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2021, 28 (SUPPL 1) : S207 - S208
  • [43] A systematic review on costs and cost-effectiveness of screening and prevention of type 2 diabetes in women with prior gestational diabetes: Exploring uncharted territory
    Werbrouck, Amber
    Schmidt, Masja
    Putman, Koen
    Benhalima, Katrien
    Verhaeghe, Nick
    Annemans, Lieven
    Simoens, Steven
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 147 : 138 - 148
  • [44] Cost-effectiveness and budget impact of heat-stable carbetocin compared to oxytocin and misoprostol for the prevention of postpartum hemorrhage (PPH) in women giving birth in India
    Cook, John R.
    Saxena, Kunal
    Taylor, Catharine
    Jacobs, Jeffrey L.
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [45] Cost-effectiveness and budget impact of heat-stable carbetocin compared to oxytocin and misoprostol for the prevention of postpartum hemorrhage (PPH) in women giving birth in India
    John R. Cook
    Kunal Saxena
    Catharine Taylor
    Jeffrey L. Jacobs
    BMC Health Services Research, 23
  • [46] Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years
    Jin, Xian Wen
    Lipold, Laura
    Foucher, Julie
    Sikon, Andrea
    Brainard, Jennifer
    Belinson, Jerome
    Schramm, Sarah
    Nottingham, Kelly
    Hu, Bo
    Rothberg, Michael B.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2016, 31 (11) : 1338 - 1344
  • [47] Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age (vol 127, pg 955, 1997)
    Salzmann, P
    Kerlikowske, K
    Phillips, K
    ANNALS OF INTERNAL MEDICINE, 1998, 128 (10) : 878 - 878
  • [48] Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years
    Xian Wen Jin
    Laura Lipold
    Julie Foucher
    Andrea Sikon
    Jennifer Brainard
    Jerome Belinson
    Sarah Schramm
    Kelly Nottingham
    Bo Hu
    Michael B. Rothberg
    Journal of General Internal Medicine, 2016, 31 : 1338 - 1344
  • [49] Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults >=60 years of age in Lao People's Democratic Republic
    Ortega-Sanchez, Ismael R.
    Mott, Joshua A.
    Kittikraisak, Wanitchaya
    Khanthamaly, Viengphone
    McCarron, Margaret
    Keokhonenang, Soukphadeth
    Ounaphom, Phonepaseuth
    Pathammavong, Chansay
    Phounphenghack, Kongxay
    Sayamoungkhoun, Panome
    Chanthavilay, Phetsavanh
    Bresee, Joseph
    Tengbriacheu, Chankham
    VACCINE, 2021, 39 (52) : 7633 - 7645
  • [50] SHOULD ROUTINE GYNECOLOGIC CARE INCLUDE SCREENING TO IDENTIFY UNDETECTABLE ANTI-MULLERIAN HORMONE LEVELS? ANALYSIS OF RESULTS FROM OVER 18,000 REPRODUCTIVE-AGE WOMEN.
    Briggs, Sharon
    Shirazi, Talia
    Hershlag, Avner
    FERTILITY AND STERILITY, 2021, 116 (03) : E68 - E68